Literature DB >> 21156720

Impaired myocardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome.

Subha V Raman1, Kavita Phatak, J Chad Hoyle, Michael L Pennell, Beth McCarthy, Tam Tran, Thomas W Prior, John W Olesik, Anthony Lutton, Chelsea Rankin, John T Kissel, Roula Al-Dahhak.   

Abstract

AIMS: Cardiomyopathy produces significant mortality in patients with Friedreich ataxia (FA), a genetic disorder that produces intra-mitochondrial iron accumulation. We sought to test the hypothesis that abnormal myocardial perfusion reserve and fibrosis represent early manifestations of cardiomyopathy. METHODS AND
RESULTS: Twenty-six patients with genetically proven FA ages 36 ± 12 years without cardiomyopathy and eight controls underwent cardiac magnetic resonance with adenosine. Precontrast imaging for myocardial iron estimation was performed. Myocardial perfusion reserve index (MPRI) was quantified using the normalized upslope of myocardial enhancement during vasodilator stress vs. rest. Left ventricular (LV) mass and volumes were computed from short-axis cine images. Serologies included lipids, and platelets were isolated for iron quantification using inductively coupled plasma mass spectrometry. Left ventricular ejection fraction and mass averaged 64.1 ± 8.3% and 62.7 ± 16.7 g/m², respectively, indicating preserved systolic function and absence of significant hypertrophy. Myocardial perfusion reserve index quantification revealed significantly lower endocardial-to-epicardial perfusion reserve in patients vs. controls (0.80 ± 0.18 vs. 1.22 ± 0.36, P = 0.01). Lower MPRI was predicted by increased number of metabolic syndrome (met-S) features (P < 0.01). Worse concentric remodelling occurred with increased GAA repeat length (r = 0.64, P < 0.001). Peripheral platelet iron measurement showed no distinction between patients and controls (5.4 ± 8.5 × 10⁻⁷ vs. 5.5 ± 2.9 × 10⁻⁷ ng/platelet, P = 0.88), nor did myocardial T2* measures.
CONCLUSIONS: Patients with FA have abnormal myocardial perfusion reserve that parallels met-S severity. Impaired perfusion reserve and fibrosis occur in the absence of significant hypertrophy and prior to clinical heart failure, providing potential therapeutic targets for stage B cardiomyopathy in FA and related myocardial diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21156720      PMCID: PMC3106287          DOI: 10.1093/eurheartj/ehq443

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  35 in total

1.  How we perform delayed enhancement imaging.

Authors:  Raymond J Kim; Dipan J Shah; Robert M Judd
Journal:  J Cardiovasc Magn Reson       Date:  2003-07       Impact factor: 5.364

Review 2.  Is the failing heart energy starved? On using chemical energy to support cardiac function.

Authors:  Joanne S Ingwall; Robert G Weiss
Journal:  Circ Res       Date:  2004-07-23       Impact factor: 17.367

3.  Measuring Friedreich ataxia: Interrater reliability of a neurologic rating scale.

Authors:  S H Subramony; W May; D Lynch; C Gomez; K Fischbeck; M Hallett; P Taylor; R Wilson; T Ashizawa
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

4.  Frataxin shows developmentally regulated tissue-specific expression in the mouse embryo.

Authors:  S Jiralerspong; Y Liu; L Montermini; S Stifani; M Pandolfo
Journal:  Neurobiol Dis       Date:  1997       Impact factor: 5.996

5.  Body-mass index and mortality in a prospective cohort of U.S. adults.

Authors:  E E Calle; M J Thun; J M Petrelli; C Rodriguez; C W Heath
Journal:  N Engl J Med       Date:  1999-10-07       Impact factor: 91.245

6.  Clinical and genetic abnormalities in patients with Friedreich's ataxia.

Authors:  A Dürr; M Cossee; Y Agid; V Campuzano; C Mignard; C Penet; J L Mandel; A Brice; M Koenig
Journal:  N Engl J Med       Date:  1996-10-17       Impact factor: 91.245

7.  Mitochondrial sources of H2O2 generation play a key role in flow-mediated dilation in human coronary resistance arteries.

Authors:  Yanping Liu; Hongtao Zhao; Hongwei Li; B Kalyanaraman; Alfred C Nicolosi; David D Gutterman
Journal:  Circ Res       Date:  2003-08-14       Impact factor: 17.367

8.  Identification of a missense mutation in a Friedreich's ataxia patient: implications for diagnosis and carrier studies.

Authors:  C Bartolo; J R Mendell; T W Prior
Journal:  Am J Med Genet       Date:  1998-10-12

9.  Cardiac involvement in Friedreich's ataxia: a clinical study of 75 patients.

Authors:  J S Child; J K Perloff; P M Bach; A D Wolfe; S Perlman; R A Kark
Journal:  J Am Coll Cardiol       Date:  1986-06       Impact factor: 24.094

10.  Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion.

Authors:  V Campuzano; L Montermini; M D Moltò; L Pianese; M Cossée; F Cavalcanti; E Monros; F Rodius; F Duclos; A Monticelli; F Zara; J Cañizares; H Koutnikova; S I Bidichandani; C Gellera; A Brice; P Trouillas; G De Michele; A Filla; R De Frutos; F Palau; P I Patel; S Di Donato; J L Mandel; S Cocozza; M Koenig; M Pandolfo
Journal:  Science       Date:  1996-03-08       Impact factor: 47.728

View more
  29 in total

1.  Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death.

Authors:  Katherine C Wu; Gary Gerstenblith; Eliseo Guallar; Joseph E Marine; Darshan Dalal; Alan Cheng; Eduardo Marbán; João A C Lima; Gordon F Tomaselli; Robert G Weiss
Journal:  Circ Cardiovasc Imaging       Date:  2012-01-20       Impact factor: 7.792

Review 2.  Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis, Prognosis, and Treatment of Infiltrative Cardiomyopathies.

Authors:  Praveen G Ranganath; Albree Tower-Rader
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 2.931

3.  Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle.

Authors:  Vidhya Kumar; Henry Chang; David A Reiter; David P Bradley; Martha Belury; Shana E McCormack; Subha V Raman
Journal:  J Vis Exp       Date:  2017-01-19       Impact factor: 1.355

4.  Cardiomyopathy of Friedreich's ataxia: use of mouse models to understand human disease and guide therapeutic development.

Authors:  R Mark Payne; P Melanie Pride; Clifford M Babbey
Journal:  Pediatr Cardiol       Date:  2011-03-01       Impact factor: 1.655

Review 5.  Untangling autophagy measurements: all fluxed up.

Authors:  Roberta A Gottlieb; Allen M Andres; Jon Sin; David P J Taylor
Journal:  Circ Res       Date:  2015-01-30       Impact factor: 17.367

Review 6.  [Heart involvement in Friedreich's ataxia].

Authors:  F Weidemann; F Scholz; C Florescu; D Liu; K Hu; S Herrmann; G Ertl; S Störk
Journal:  Herz       Date:  2014-05-23       Impact factor: 1.443

Review 7.  Emerging therapies in Friedreich's Ataxia.

Authors:  Theresa A Zesiewicz; Joshua Hancock; Shaila D Ghanekar; Sheng-Han Kuo; Carlos A Dohse; Joshua Vega
Journal:  Expert Rev Neurother       Date:  2020-09-21       Impact factor: 4.618

8.  Impact of baseline calibration on semiquantitative assessment of myocardial perfusion reserve by adenosine stress MRI.

Authors:  Andreas Seitz; Giancarlo Pirozzolo; Udo Sechtem; Raffi Bekeredjian; Peter Ong; Heiko Mahrholdt
Journal:  Int J Cardiovasc Imaging       Date:  2019-11-14       Impact factor: 2.357

Review 9.  The role of stress cardiac magnetic resonance in women.

Authors:  Andrea Cardona; Karolina M Zareba; Subha V Raman
Journal:  J Nucl Cardiol       Date:  2016-07-25       Impact factor: 5.952

10.  Serum versus Imaging Biomarkers in Friedreich Ataxia to Indicate Left Ventricular Remodeling and Outcomes.

Authors:  Nishaki Mehta; Paul Chacko; James Jin; Tam Tran; Thomas W Prior; Xin He; Gunjan Agarwal; Subha V Raman
Journal:  Tex Heart Inst J       Date:  2016-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.